Shattuck Labs, Inc. (STTK): Entry into a Material Definitive Agreement
Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d163713dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version Shattuck Labs, Inc. 10,879,376 Shares of Common Stock Pre-Funded Warrants to Purchase 7,870,624 Shares of Common Stock ($0.0001 par value) Underwriting Agreement June 9, 2026 Leerink Partners LLC J.P. Morgan Se
How this was made
The 30-second read
Why it matters
Traders should focus on the final prospectus supplement for pricing, discount vs. market, warrant terms, and stated use of proceeds; those determine whether the market treats the raise as manageable or value-destructive.
Market read
Primary disclosure of a dilutive financing package for STTK; likely to drive near-term volatility until pricing and proceeds are known.
What to watch
The excerpt lacks offering price, net proceeds, and stated use of funds—those details can flip the read-through from dilution-only to milestone-driven.
Background
The SEC 8-K (Item 1.01) reports entry into a material definitive underwriting agreement for an equity offering including firm common shares and pre-funded warrants, with an option for additional shares.
Ticker impact
Shattuck Labs entered a material definitive underwriting agreement to sell 10,879,376 common shares plus pre-funded warrants for 7,870,624 shares.
Bias toward near-term downside/volatility as dilution overhangs; magnitude depends on offering price and use of proceeds (not provided in excerpt).
An 8-K underwriting agreement is a primary disclosure of a capital raise; pre-funded warrants typically signal financing needs and can weigh on the stock until pricing/terms are digested.
Market effects
Biopharma small/mid-cap financing via common + pre-funded warrants can reinforce risk premium for cash-burn names.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited; primarily affects STTK and comparable US-listed biotech issuers.
Counterpoint
If proceeds fund de-risking milestones (e.g., trials/IND-enabling work), the dilution could be viewed as strategic rather than purely negative.
Key entities
- issuerShattuck Labs, Inc.
Company filing the 8-K and entering the underwriting agreement for the equity offering.
- deal_partiesUnderwriters (Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler & Co., Cantor Fitzgerald & Co.)
Named representatives/underwriters for the firm shares, pre-funded warrants, and potential option shares.
